Development of new technologies to address the problem of diabetes in aviation

Prof. Felice Strollo Vicepresident AIMAS - Secretary General ESAM Lecturer at DISFEB, Milan University, Italy

> 1° AMDA Congress Moscow 17-20 October 2018

> > 1

### In memory of my father, Prof. Mario Strollo

- He was a 2<sup>nd</sup> world war MD prisoner and he loved Russian people as open and friendly
- as the first Italian Air Force psychologist he performed human factor studies for safety in aersopace medicine and had good Russian contacts during Gagarins' period
- flying on insulin is a real flight safety issue and has huge human factor implications
- a good compromise is needed among safety issues, longevity and life challenges including employment and selfconfidence
- The Russian scietific long standing experience in the field and the deep humanistic culture of Russian people might strongly contribute to updating diabetes related AMC list


# **Diabetes prevalence** is increasing all over the world 9.1% 2017


9.1% 2017 2000

11.7%

2045


### DM prevalence worldwide





### The trend is overwhelming!

### In **2045...**



### Acceptable Means of Compliance - AMC

European Aviation Safety Agency

Acceptable Means of Compliance

and

Guidance Material to Part-MED<sup>1</sup>

Initial issue 15 December 2011

### PART – MED for:

- 1<sup>st</sup> Class Pilots
- 2<sup>nd</sup> Class Pilots
- LAPL
- Cabin Crew

<sup>&</sup>lt;sup>1</sup> Acceptable Means of Compliance and Guidance Material to Commission Regulation (EU) No 1178/2011 of 3 November 2011 laying down technical requirements and administrative procedures related to civil avoition aircrew pursuant to Regulation (EC) No 216/2008 of the European Parliament and of the Council.

#### **MED.B.025** Metabolic and Endocrine Systems

#### **AMC1-2 MED.B.025 – AMC5 MED.B.095**

Diabetes mellitus Type 1: Class 1, Class 2, LAPL: UNFIT

Diabetes mellitus Type 2 - Non Hypoglycaemic Treatment

Biguanides Glitazones Gliptins *GLP-1 receptor agonists* Alfa glucosidase inhibitors (*Acarbose*)


Class 1: OML (deferral)
Class 2: FIT (consultation)
LAPL: FIT (no consultation)

**Diabetes mellitus Type 2 treated with insulin:** 

Class 1, Class 2: UNFIT;

LAPL: FIT with limitations and specific surveillance protocols

### **Consequences of hypoglycaemia**



1: Whitmer RA et al JAMA 2009, 301:1565-1572

2: Zammitt NN et al Diabetes Care 2005, 28:2948-2961

3 Canadian Diabetes Association's Clinical Practice Guidelines for Diabetes and Private and Commercial Driving. Canadian Journal Of Diabetes. 2003;27(2):128-140. 4:Jönsson L et al. Cost of Hypoglycemia in Patients with Type 2 Diabetes in Sweden. Value In Health. 2006; 9: 193-198

5: Barnett AH, CMRO 26, 1333-1342, 2010

6. Foley J & Jordan J, Vascular Health Risk Management, 2010 6:541-548

# **Diabetes drugs and hypoglycemia**

High risk <sup>1,2</sup>	Low risk <sup>1,2</sup>
Insulin	Metformin
Sulphonylureas	$\alpha$ -glucosidase inhibitors
Glinides	Thiazolidinediones
	GLP-1 receptor agonists
	DPP-4 inhibitors

1. Nathan DM, et al. Diabetologia. 2009;52:17-306. 2. Cefalu WT. Nature. 2007;81:636-49.

### Solutions

(3) Applicants with diabetes mellitus Type 2 treated with insulin may be assessed as fit with limitations for revalidation if blood sugar control has been achieved and the process under (e) and (f) below is followed. An OSL limitation is required.

A TML limitation for 12 months may be needed to ensure compliance with the follow-up requirements below. Licence privileges should be restricted to aeroplanes and sailplanes only.

### SOLUTIONS (CONT'D 1)

(e) Aero-medical assessment by, or under the guidance of, the licensing authority:

(1) A diabetology review at yearly intervals....

(2) Ophthalmological review at yearly intervals....

(3) Blood testing at 6-monthly intervals:

(i) HbA1c: target is 7,5–8,5 %;

(ii) renal profile;

(iii) liver profile;

(iv) lipid profile.

# SOLUTIONS (CONT'D 2)

### (f) <u>Pilot responsibility</u>

Blood sugar testing is carried out during nonoperational and operational periods ..... Pilots should prove to AME or AeMC or licencing authority that testing has been performed as indicated below and with which results.

(1) <u>Testing during non-operational periods</u>:

normally 3-4 times/day or as recommended by the treating physician, and or any awareness of hypoglycemia

### SOLUTIONS (CONT'D 3)

#### (f) Pilot responsibility

- (2) <u>Testing frequency during operational periods</u>:
  - (i) 120 min. before departure;
  - (ii) <30 min. before departure;
  - (iii) 60 min. during flight;
  - (iv) 30 min. before landing;
- (3) <u>Actions following glucose testing</u>:
  - (i) 120 min. before departure: if the test result is >15 mmol/l, piloting should not be commenced
  - (ii) 10-15g of carbohydrate should be ingested and a retest performed within 30 minutes if:
    - (A) any test result is <4,5 mmol/l
    - (B) the pre-landing test measurement is missed or a subsequent go-around/diversion is performed




# Dr. Punita-Masrani's Algorithm


#### Diagnosis


- 1) Likelihood of mediacl incapacitation
- 2) Likelihoood of unacceptable outcome inflight
- 3) Risk acceptable
- 4) Risk after likelihood modification
- 5) Manage consequences

**Risk acceptable after consequence modification** 



### A one glucose day profile








#### diabetes

Antonio Ceriello\*

Chair of Endocrinology, University of Udine, Italy




# Various CGMS devices

<u>Guardian REAL-</u> <u>Time</u>			Abbott FreeStyle Navigator®
			Navigator


#### **CGM Benefits**

HbA1c decreases independently of age and insulin injection method



Data on File. T1D Exchange (Boston, April 2015); referred also by: Graham C et al. Continuous Glucose Monitoring (CGM) Use in Type 1 Diabetes: Database Analysis Shows Meaningful Improvements in A1c. Diabetes 2015; 64 (Supp 1): A-180-OR

### Web based CGM data sharing for interpretation and decision making



### **MAIN CHARACTERISTICS**

#### Components


- 1. Sensor: electrohcemical
- 2. Trasmitter: via bluetooth to the app and / or receiver



**3. Display:**shows trends and sendsout alarms



### Receiver



Original Article Discrepancies Between Blood Glucose and Interstitial Glucose—Technological Artifacts or Physiology: Implications for Selection of the Appropriate Therapeutic Target




Are ISFG (interstitial fluid glucose) and BG (blood glucose) interchangeable as for decision making?


Blood takes glucose everywhere in the body, ISF only to closer cells

□ BG reflects overall available glucose amount, ISFG depends on local changes (blood to ISF transfer rate and tissue utlization rate)

from a physiological point of view, tissue (and especially brain) glucose concentrations provide sounder information than circulating levels CGM Glucose (mg/dL)




### Average sensor time lag versus blood glucose



DIABETES TECHNOLOGY & THERAPEUTICS Volume 11, Number 11, 2009

# Lag Time



https://studies.jaeb.org/ndocs/extapps/CGMTeaching/User/Introduction.aspx

Toward Calibration-Free Continuous Glucose Monitoring Sensors: Bayesian Calibration Approach Applied to Next-Generation Dexcom Technology

DIABETES TECHNOLOGY & THERAPEUTICS Volume 20, Number 1, 2018 Mary Ann Liebert, Inc. DOI: 10.1089/dia.2017.0297

#### **RESULTS:**

The one-per-day and one-every-two-days calibration scenarios in the nextgeneration CGM data have an accuracy of 8.5% MARD (vs. 11.59% of DG4P) and 8.4% MARD (vs. 11.63% of DG4P), respectively. Accuracy slightly worsens to 9.2% (vs. 11.62% of DG4P) when calibrations are reduced to one-every-four-days. The calibration-free scenario results in 9.3% MARD (vs. 12.97% of DG4P).

#### **CONCLUSIONS**:

In next-generation Dexcom CGM sensor data, the use of an online calibration algorithm based on a multiple-day model of sensor time variability and Bayesian parameter estimation aids in the shift toward a calibration-free scenario with even better results than those obtained in present-generation sensors. Replacement of Blood Glucose Measurements by Measurements With Systems for Real-Time Continuous Glucose Monitoring (rtCGM) or CGM With Intermittent Scanning (iscCGM): A German View

Journal of Diabetes Science and Technology 2017, Vol. 11(4) 653-656

The extent of use as replacement for BGSM and exceptional situations in which the manufacturers of the two systems regard additional BGSM as necessary are described in the instructions for use (at least those used in Germany) as follows:

With the Dexcom G5 therapeutic decisions may only be mad :

- if glucose values and warnings comply with symptoms and expectations
- if the instructions were followed and the system was calibrated 12 hours after the initial calibration
- on the basis of the tissue glucose value, trend arrow, trend diagram, and/or attainable warnings
- if at least three consecutive measurement results from the last 15 minutes are available

When using FreeStyle Libre, additional blood glucose measurements have to be performed:

- In phases of rapidly changing glucose values
- To confirm a sensor-reported hypoglycemia or impending hypoglycemia
- If symptoms do not comply with the glucose value displayed by the system

use CGM non-adjunctively to adjust their insulin doses

- Today, although this procedure is not approved, many persons with diabetes use CGM non-adjunctively to adjust their insulin doses (Endocr Pract 2015;21: 613–620)
- FDA Advisory Panel Votes to Recommend Non-Adjunctive Use of Dexcom G5 Mobile CGM (DIABETES TECHNOLOGY & THERAPEUTICS Volume 18, Number 8, 2016):

### FDA Advisory Panel Votes to Recommend Non-Adjunctive Use of Dexcom G5 Mobile CGM

- 1. Is there reasonable assurance that the Dexcom G5 CGM is safe for the proposed indications for use? : 8 yes/2 no
- 2. Is there reasonable assurance that the Dexcom G5 is effective for the proposed indications for use? : 9 yes/1 no
- 3. Do the benefits of the Dexcom G5 CGM for the proposed indications for use outweigh the risks for the proposed indications for use? : 8 yes/2 no

The Advisory Committee concluded that the G5 is sufficiently safe and effective for nonadjunctive use to guide diabetes treatment decisions, and that the benefits of its use in this way outweigh the risks.


The Dexcom G5 Mobile has EMEA (European) approval for non-adjunctive use

DIABETES TECHNOLOGY & THERAPEUTICS Volume 18, Number 8, 2016

New Approach to Adjusting Insulin Doses Using Trend Arrows in Adults: Pre-meal and Corrections ≥4 Hours Post-meal

Trend Arrows		Correction	Insulin Dose				
Receiver	Арр	Factor* (CF)	Adjustment (U)				
**	٥	<25 25-<50 50-<75 ≥75	+4.5 +3.5 +2.5 +1.5				
+		<25 25-<50	+3.5 +2.5	Trend Ar	rows	Correction	Insulin Dose
-	$\cup$	50-<75 ≥75	+1.5 +1.0	Receiver	Арр	Factor* (CF)	Adjustment (U)
*	0	<25 25-<50 50-<75 ≥75	+2.5 +1.5 +1.0 +0.5	<b>†</b> †	$\bigcirc$	<25 25-<50 50-<75	+4.5 +3.5 +2.5
•	$\bigcirc$	<25 25-<50 50-<75 ≥75	No adjustment No adjustment No adjustment No adjustment		A	≥75 <25	+1.5 +3.5
*	0	<25 25-<50 50-<75	-2.5 -1.5 -1.0	•	$\circ$	25-<50 50-<75 ≥75	+2.5 +1.5 +1.0
ŧ	$\bigcirc$	≥75 <25 25-<50 50-<75 ≥75	-0.5 -3.5 -2.5 -1.5 -1.0		0	<25 25-<50 50-<75 ≥75	+2.5 +1.5 +1.0 +0.5
++	$\bigcirc$	<25 25-<50 50-<75 ≥75	-4.5 -3.5 -2.5 -1.5				and Mine-

December 2017 | Vol. 1, Iss. 12 Journal of the Endocrine Society | 1445–1460



# Dr. Punita-Masrani's Algorithm

Diagnosis

- 1) Likelihood of mediacl incapacitation
- 2) Likelihoood of unacceptable outcome inflight
- 3) Risk acceptable
- 4) Risk after likelihood modification
- 5) Manage consequences

**RISK ACCEPTABLE AFTER CONSEQUENCE MODIFICATION** 

### **PILOTS ON INSULIN**



### Let's try to build up confidence and trust